Vertex Pharmaceuticals Incorporated which can be found using ticker (VRTX) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $574.00 and $325.00 calculating the mean target share price we have $465.33. (at the time of writing). Given that the stocks previous close was at $412.11 and the analysts are correct then there would likely be a percentage uptick in value of 12.9%. It’s also worth noting that there is a 50 day moving average of $424.15 while the 200 day moving average is $375.89. The company has a market capitalization of 107.38B. The stock price is currently at: $415.71 USD
The potential market cap would be $121,248,459,853 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 29.93, revenue per share of $38.30 and a 13.17% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
